Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 4, 2009

Nanogen Licenses Technology to Quest for In Vitro Diagnostic Testing

  • Quest Diagnostics obtained rights to use and sell products and services incorporating Nanogen’s MGB (minor groove binder) Probe technology. According to the end-user license agreement, Quest will pay an up-front fee and royalties on tests sold using this technology. Quest will be able to use this platform in human in vitro diagnostic testing.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »